Compare Charles River Laboratories Intl. Inc (CRL) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Invesco Preferred ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Invesco Preferred ETF trades at $10.02 (market cap $3.60B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4× Invesco Preferred ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Invesco Preferred ETF for 95 Days on average.
| CRL | PGX | |
|---|---|---|
Market Cap | $14.23B | $3.60B |
Volume | 1,176,885 | 5,986,026 |
Sector | Health | — |
52-Week High | $310.77 | $11.61 |
52-Week Low | $149.93 | $9.97 |
Typical Hold Time | 33 Days | 95 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
PGX trades at $10.01, up 0.4% with bearish technical indicators showing 18 sell signals versus 3 buy signals. The stock faces resistance at $10 with RSI at neutral levels. Recent dividends of $0.06 were declared for July and September 2026, providing income potential amid technical weakness.
The outlook remains cautious with strong bearish momentum in moving averages. Investment opportunity lies in dividend yield while risks include technical breakdown below $10 support. Fundamental analysis is limited without current financial ratios, requiring updated SEC filings for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
